NIPH Clinical Trials Search

JRCT ID: jRCT2071210048

Registered date:30/07/2021

Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Basic Information

Recruitment status Not Recruiting
Health condition(s) or Problem(s) studiedCholestatic Pruritus in Participants With Primary Biliary Cholangitis
Date of first enrollment27/10/2021
Target sample size25
Countries of recruitmentArgentina,Japan,Belgium,Japan,Brazil,Japan,Bulgaria,Japan,Canada,Japan,China,Japan,France,Japan,Germany,Japan,Italy,Japan,Mexico,Japan,Poland,Japan,Russian Federation,Japan,United Kingdom,Japan,United States,Japan
Study typeInterventional
Intervention(s)- Drug. Linerixibat Participants will receive linerixibat. - Drug. Placebo Participants will receive placebo.


Primary OutcomeChange from Baseline in Monthly Itch Scores over 24 weeks using Numerical Rating Scale (NRS) [ Time Frame: Baseline and up to 24 weeks ] Monthly Itch Score will be assessed using an NRS, ranging from 0 to 10, where 0 represents no itching and 10 the worst imaginable itching.
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 18age old
Age maximum<= 80age old
Include criteria- Male and female participants must be between 18 to 80 years of age inclusive, at the time of signing the informed consent. - Participants who have documented PBC. - Participants who have moderate to severe itch.
Exclude criteriaSymptoms suggestive of active coronavirus disease 2019 (COVID-19) infection whilst symptoms persist or known COVID-19 positive contacts within the past 14 days should be excluded for at least 14 days from the exposure. Total bilirubin >2.0 times Upper Limit of Normal (ULN) using the average of two Baseline measures. Screening Alanine Aminotransferase (ALT) > 6 times ULN in a single Baseline measure or ALT > 5 times ULN using the average of two Baseline measures. Screening estimated glomerular filtration rate (eGFR) <30 milliliter per minute per 1.73 square meter (mL/min/1.73m(hat[symbol])2). History or presence of hepatic decompensation (e.g., variceal bleeding, hepatic encephalopathy or ascites). Presence of actively replicating viral hepatitis B or C (HBV, HCV) infection, primary sclerosing cholangitis (PSC), alcoholic liver disease and/or confirmed hepatocellular carcinoma or biliary cancer. Current clinically significant diarrhea or active inflammatory ileal disease according to Investigator's clinical judgment. Current symptomatic cholelithiasis or cholecystitis. Current diagnosis of primary skin disorders with itch symptoms (e.g., atopic dermatitis, psoriasis). Primary sleep disorders such as but are not limited to sleep apnea, narcolepsy, hypersomnia. Current/previous diagnosis of colorectal cancer. Initiation, discontinuation or change in dose of ursodeoxycholic acid (UDCA), bezafibrate or fenofibrate in the 8 weeks prior to Screening. Use of obeticholic acid: within 8 weeks prior to Screening. (Participants may not initiate or restart during the study). Initiation, discontinuation, or change in dose of any of the following in the 8 weeks prior to Screening: bile acid binding resins, rifampicin, naltrexone, naloxone, nalfurafine, pregabalin, gabapentin, sertraline or other selective serotonin reuptake inhibitor (SSRIs), antihistamines used for the treatment of itching. Administration of any other human ileal bile acid transporter (IBAT) inhibitor in the 12 weeks prior to screening. Any planned procedures intended to treat cholestatic pruritus such as nasobiliary drainage or ultraviolet light therapy from Screening and throughout the study. History of sensitivity or intolerance to the study treatment.

Related Information


Public contact
Name Yasutoshi Okawa
Address Akasaka Intercity AIR, 1-8-1 Akasaka, Minato-ku, Tokyo, Japan Tokyo Japan 107-0052
Telephone +81-120-561-007
Affiliation GlaxoSmithKline K.K.
Scientific contact
Name Arisa Okamasa
Address Akasaka Intercity AIR, 1-8-1 Akasaka, Minato-ku, Tokyo, Japan Tokyo Japan 107-0052
Telephone +81-120-561-007
Affiliation GlaxoSmithKline K.K.